



Clinical trial results:

A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of MK-7684A (MK-7684 [Vibostolimab] with MK-3475 [Pembrolizumab] Coformulation) in Participants with Relapsed or Refractory Hematological Malignancies

Summary

EudraCT number	2021-001700-15
Trial protocol	DE DK FR ES PL IT HU
Global end of trial date	10 December 2024

Results information

Result version number	v1 (current)
This version publication date	21 December 2025
First version publication date	21 December 2025

Trial information

Trial identification

Sponsor protocol code	7684a-004
-----------------------	-----------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT05005442
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Merck Sharp & Dohme LLC
Sponsor organisation address	126 East Lincoln Avenue, P.O. Box 2000, Rahway, NJ, United States, 07065
Public contact	Clinical Trials Disclosure, Merck Sharp & Dohme LLC, ClinicalTrialsDisclosure@MSD.com
Scientific contact	Senior Vice President, Global Clinical Development, Merck Sharp & Dohme LLC, ClinicalTrialsDisclosure@MSD.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	10 December 2024
Is this the analysis of the primary completion data?	Yes
Primary completion date	10 December 2024
Global end of trial reached?	Yes
Global end of trial date	10 December 2024
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The purpose of the study is to determine the safety and tolerability of pembrolizumab/vibostolimab (MK-7684A) in hematological malignancies. This study will also evaluate the overall response rate (ORR), the duration of response (DOR), and disease control rate (DCR) following administration of pembrolizumab/vibostolimab. In addition, this study will characterize pharmacokinetic (PK) profile of vibostolimab (MK-7684).

Protection of trial subjects:

This study was conducted in conformance with Good Clinical Practice standards and applicable country and/or local statutes and regulations regarding ethical committee review, informed consent, and the protection of human subjects participating in biomedical research.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	28 September 2021
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Brazil: 7
Country: Number of subjects enrolled	Canada: 4
Country: Number of subjects enrolled	Chile: 8
Country: Number of subjects enrolled	Denmark: 12
Country: Number of subjects enrolled	France: 13
Country: Number of subjects enrolled	Germany: 4
Country: Number of subjects enrolled	Hungary: 20
Country: Number of subjects enrolled	Israel: 23
Country: Number of subjects enrolled	Italy: 15
Country: Number of subjects enrolled	Poland: 21
Country: Number of subjects enrolled	Russian Federation: 8
Country: Number of subjects enrolled	Spain: 10
Country: Number of subjects enrolled	Taiwan: 4
Country: Number of subjects enrolled	Türkiye: 17
Country: Number of subjects enrolled	Ukraine: 9
Country: Number of subjects enrolled	United States: 17
Worldwide total number of subjects	192
EEA total number of subjects	95

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	122
From 65 to 84 years	66
85 years and over	4

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

One hundred ninety-two participants were allocated, 1 participant was allocated but did not receive treatment due to worsening of underlying disease. No participants were enrolled into Part 2 of the study (The study was closed with amendment 5 after the last subject completed 35 cycles of the first course of Part 1).

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Cohort A Pembrolizumab/vibostolimab coformulation

Arm description:

Participants with classic Hodgkin's lymphoma (cHL) or primary mediastinal Bcell lymphoma (PMBCL) who are relapsed or refractory to at least 1 line of prior therapy (cHL) of at least 2 lines of prior therapies (PMBCL) received pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous IV infusion once every 3 weeks (Q3W) for up to 35 cycles up to approximately 2 years.

Arm type	Experimental
Investigational medicinal product name	Pembrolizumab/vibostolimab coformulation
Investigational medicinal product code	
Other name	MK7684A
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Pembrolizumab 200 mg + vibostolimab 200 mg/20 mL vial IV infusion

Arm title	Cohort B Pembrolizumab/vibostolimab coformulation
------------------	---

Arm description:

Participants with cHL or PMBCL who are relapsed or refractory to at least 2 lines of prior therapies (cHL) of at least 3 lines of prior therapies (PMBCL) received pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous IV infusion once every 3 weeks (Q3W) for up to 35 cycles up to approximately 2 years.

Arm type	Experimental
Investigational medicinal product name	Pembrolizumab/vibostolimab coformulation
Investigational medicinal product code	
Other name	MK7684A
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Pembrolizumab 200 mg + vibostolimab 200 mg/20 mL vial IV infusion

Arm title	Cohort C Pembrolizumab/vibostolimab coformulation
------------------	---

Arm description:

Participants with relapsed or refractory follicular lymphoma (FL) following at least 2 lines of therapy received pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous IV infusion once every 3 weeks (Q3W) for up to 35 cycles up to approximately 2 years.

Arm type	Experimental
Investigational medicinal product name	Pembrolizumab/vibostolimab coformulation
Investigational medicinal product code	
Other name	MK7684A
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Pembrolizumab 200 mg + vibostolimab 200 mg/20 mL vial IV infusion

Arm title	Cohort D Pembrolizumab/vibostolimab coformulation
------------------	---

Arm description:

Participants with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) following at least 2 lines of therapy received pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous IV infusion once every 3 weeks (Q3W) for up to 35 cycles up to approximately 2 years.

Arm type	Experimental
Investigational medicinal product name	Pembrolizumab/vibostolimab coformulation
Investigational medicinal product code	
Other name	MK7684A
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Pembrolizumab 200 mg + vibostolimab 200 mg/20 mL vial IV infusion

Arm title	Cohort E Pembrolizumab/vibostolimab coformulation
------------------	---

Arm description:

Participants with relapsed or refractory multiple myeloma (MM) following at least 3 lines of therapy and have exhausted all approved lines of therapy received pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous IV infusion once every 3 weeks (Q3W) for up to 35 cycles up to approximately 2 years.

Arm type	Experimental
Investigational medicinal product name	Pembrolizumab/vibostolimab coformulation
Investigational medicinal product code	
Other name	MK7684A
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Pembrolizumab 200 mg + vibostolimab 200 mg/20 mL vial IV infusion

Arm title	Cohort F Pembrolizumab/vibostolimab coformulation
------------------	---

Arm description:

Participants with relapsed or refractory non-Hodgkin's lymphoma (NHL) following at least 2 lines of therapy received pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous IV infusion once every 3 weeks (Q3W) for up to 35 cycles up to approximately 2 years.

Arm type	Experimental
Investigational medicinal product name	Pembrolizumab/vibostolimab coformulation
Investigational medicinal product code	
Other name	MK7684A
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Pembrolizumab 200 mg + vibostolimab 200 mg/20 mL vial IV infusion

Number of subjects in period 1	Cohort A Pembrolizumab/vibo stolimab coformulation	Cohort B Pembrolizumab/vibo stolimab coformulation	Cohort C Pembrolizumab/vibo stolimab coformulation
Started	42	42	20
Treated	42	42	20
Completed	0	0	0
Not completed	42	42	20
Adverse event, serious fatal	14	10	8
Consent withdrawn by subject	2	2	1
Physician decision	-	-	1
Site terminated by sponsor	-	2	-
Sponsor decision	26	26	10
Lost to follow-up	-	2	-

Number of subjects in period 1	Cohort D Pembrolizumab/vibo stolimab coformulation	Cohort E Pembrolizumab/vibo stolimab coformulation	Cohort F Pembrolizumab/vibo stolimab coformulation
Started	30	25	33
Treated	30	25	32
Completed	0	0	0
Not completed	30	25	33
Adverse event, serious fatal	22	13	15
Consent withdrawn by subject	3	-	5
Physician decision	-	2	-
Site terminated by sponsor	-	-	1
Sponsor decision	5	9	12
Lost to follow-up	-	1	-

Baseline characteristics

Reporting groups

Reporting group title	Cohort A Pembrolizumab/vibostolimab coformulation
Reporting group description: Participants with classic Hodgkin's lymphoma (cHL) or primary mediastinal Bcell lymphoma (PMBCL) who are relapsed or refractory to at least 1 line of prior therapy (cHL) or at least 2 lines of prior therapies (PMBCL) received pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous IV infusion once every 3 weeks (Q3W) for up to 35 cycles up to approximately 2 years.	
Reporting group title	Cohort B Pembrolizumab/vibostolimab coformulation
Reporting group description: Participants with cHL or PMBCL who are relapsed or refractory to at least 2 lines of prior therapies (cHL) or at least 3 lines of prior therapies (PMBCL) received pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous IV infusion once every 3 weeks (Q3W) for up to 35 cycles up to approximately 2 years.	
Reporting group title	Cohort C Pembrolizumab/vibostolimab coformulation
Reporting group description: Participants with relapsed or refractory follicular lymphoma (FL) following at least 2 lines of therapy received pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous IV infusion once every 3 weeks (Q3W) for up to 35 cycles up to approximately 2 years.	
Reporting group title	Cohort D Pembrolizumab/vibostolimab coformulation
Reporting group description: Participants with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) following at least 2 lines of therapy received pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous IV infusion once every 3 weeks (Q3W) for up to 35 cycles up to approximately 2 years.	
Reporting group title	Cohort E Pembrolizumab/vibostolimab coformulation
Reporting group description: Participants with relapsed or refractory multiple myeloma (MM) following at least 3 lines of therapy and have exhausted all approved lines of therapy received pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous IV infusion once every 3 weeks (Q3W) for up to 35 cycles up to approximately 2 years.	
Reporting group title	Cohort F Pembrolizumab/vibostolimab coformulation
Reporting group description: Participants with relapsed or refractory non-Hodgkin's lymphoma (NHL) following at least 2 lines of therapy received pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous IV infusion once every 3 weeks (Q3W) for up to 35 cycles up to approximately 2 years.	

Reporting group values	Cohort A Pembrolizumab/vibo stolimab coformulation	Cohort B Pembrolizumab/vibo stolimab coformulation	Cohort C Pembrolizumab/vibo stolimab coformulation
Number of subjects	42	42	20
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0

Adults (18-64 years)	35	33	11
From 65-84 years	7	9	9
85 years and over	0	0	0
Age Continuous Units: Years			
arithmetic mean	41.5	46.7	63.6
standard deviation	± 16.5	± 17.6	± 12.8
Sex: Female, Male Units: Participants			
Female	18	16	8
Male	24	26	12
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	0	0	0
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	4	1	0
White	38	35	20
More than one race	0	0	0
Unknown or Not Reported	0	6	0
Ethnicity (NIH/OMB) Units: Subjects			
Hispanic or Latino	6	3	3
Not Hispanic or Latino	36	33	15
Unknown or Not Reported	0	6	2

Reporting group values	Cohort D Pembrolizumab/vibo stolimab coformulation	Cohort E Pembrolizumab/vibo stolimab coformulation	Cohort F Pembrolizumab/vibo stolimab coformulation
Number of subjects	30	25	33
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	17	12	14
From 65-84 years	12	12	17
85 years and over	1	1	2
Age Continuous Units: Years			
arithmetic mean	60.7	64.4	66.0
standard deviation	± 12.7	± 10.8	± 14.4
Sex: Female, Male Units: Participants			
Female	15	15	13
Male	15	10	20

Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	2	2	3
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	1	3	1
White	27	20	29
More than one race	0	0	0
Unknown or Not Reported	0	0	0
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	5	1	3
Not Hispanic or Latino	22	24	29
Unknown or Not Reported	3	0	1

Reporting group values	Total		
Number of subjects	192		
Age categorical			
Units: Subjects			
In utero	0		
Preterm newborn infants (gestational age < 37 wks)	0		
Newborns (0-27 days)	0		
Infants and toddlers (28 days-23 months)	0		
Children (2-11 years)	0		
Adolescents (12-17 years)	0		
Adults (18-64 years)	122		
From 65-84 years	66		
85 years and over	4		
Age Continuous			
Units: Years			
arithmetic mean			
standard deviation	-		
Sex: Female, Male			
Units: Participants			
Female	85		
Male	107		
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	0		
Asian	7		
Native Hawaiian or Other Pacific Islander	0		
Black or African American	10		
White	169		
More than one race	0		
Unknown or Not Reported	6		
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	21		
Not Hispanic or Latino	159		

Unknown or Not Reported	12		
-------------------------	----	--	--

End points

End points reporting groups

Reporting group title	Cohort A Pembrolizumab/vibostolimab coformulation
Reporting group description: Participants with classic Hodgkin's lymphoma (cHL) or primary mediastinal Bcell lymphoma (PMBCL) who are relapsed or refractory to at least 1 line of prior therapy (cHL) or at least 2 lines of prior therapies (PMBCL) received pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous IV infusion once every 3 weeks (Q3W) for up to 35 cycles up to approximately 2 years.	
Reporting group title	Cohort B Pembrolizumab/vibostolimab coformulation
Reporting group description: Participants with cHL or PMBCL who are relapsed or refractory to at least 2 lines of prior therapies (cHL) or at least 3 lines of prior therapies (PMBCL) received pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous IV infusion once every 3 weeks (Q3W) for up to 35 cycles up to approximately 2 years.	
Reporting group title	Cohort C Pembrolizumab/vibostolimab coformulation
Reporting group description: Participants with relapsed or refractory follicular lymphoma (FL) following at least 2 lines of therapy received pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous IV infusion once every 3 weeks (Q3W) for up to 35 cycles up to approximately 2 years.	
Reporting group title	Cohort D Pembrolizumab/vibostolimab coformulation
Reporting group description: Participants with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) following at least 2 lines of therapy received pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous IV infusion once every 3 weeks (Q3W) for up to 35 cycles up to approximately 2 years.	
Reporting group title	Cohort E Pembrolizumab/vibostolimab coformulation
Reporting group description: Participants with relapsed or refractory multiple myeloma (MM) following at least 3 lines of therapy and have exhausted all approved lines of therapy received pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous IV infusion once every 3 weeks (Q3W) for up to 35 cycles up to approximately 2 years.	
Reporting group title	Cohort F Pembrolizumab/vibostolimab coformulation
Reporting group description: Participants with relapsed or refractory non-Hodgkin's lymphoma (NHL) following at least 2 lines of therapy received pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous IV infusion once every 3 weeks (Q3W) for up to 35 cycles up to approximately 2 years.	

Primary: Percentage of Participants with a Dose-Limiting Toxicity (DLT)

End point title	Percentage of Participants with a Dose-Limiting Toxicity
End point description: A DLT is defined as an event with toxicity including the type, severity, time of onset, time of resolution, and the probable association with study treatment that are not due to pre-existing conditions as defined by the Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE 5.0). Percentage of participants who experience a DLT per CTCAE 5.0 are reported. The analysis population consists of all participants who received at least one dose of study intervention and that finished the DLT evaluation period without a DLT or experienced a DLT in the DLT evaluation period.	
End point type	Primary
End point timeframe: Up to approximately 6 weeks	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Per protocol, no statistical analysis was planned for this endpoint.

End point values	Cohort A Pembrolizumab /vibostolimab coformulation	Cohort B Pembrolizumab /vibostolimab coformulation	Cohort C Pembrolizumab /vibostolimab coformulation	Cohort D Pembrolizumab /vibostolimab coformulation
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	42	41	18	20
Units: Percentage of Participants				
number (confidence interval 95%)	4.8 (0.8 to 14.2)	2.4 (0.1 to 10.8)	0.0 (0.0 to 14.6)	5.0 (0.3 to 20.8)

End point values	Cohort E Pembrolizumab /vibostolimab coformulation	Cohort F Pembrolizumab /vibostolimab coformulation		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	10	25		
Units: Percentage of Participants				
number (confidence interval 95%)	0.0 (0.0 to 23.8)	8.0 (1.4 to 22.8)		

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Participants Who Experienced an Adverse Event (AE)

End point title	Percentage of Participants Who Experienced an Adverse Event (AE) ^[2]
-----------------	---

End point description:

An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event. The number of participants who experience an AE are reported. The analysis population included all allocated participants who received at least 1 dose of study intervention.

End point type	Primary
----------------	---------

End point timeframe:

Up to approximately 27 months

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Per protocol, no statistical analysis was planned for this endpoint.

End point values	Cohort A Pembrolizumab /vibostolimab coformulation	Cohort B Pembrolizumab /vibostolimab coformulation	Cohort C Pembrolizumab /vibostolimab coformulation	Cohort D Pembrolizumab /vibostolimab coformulation
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	42	42	20	30
Units: Percentage of Participants				
number (not applicable)	92.9	97.6	95.0	80.0

End point values	Cohort E Pembrolizumab /vibostolimab coformulation	Cohort F Pembrolizumab /vibostolimab coformulation		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	25	32		
Units: Percentage of Participants				
number (not applicable)	80.0	87.5		

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Participants Who Discontinued Study Treatment Due to an AE

End point title	Percentage of Participants Who Discontinued Study Treatment Due to an AE ^[3]
-----------------	---

End point description:

An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event. The number of participants discontinued from the study treatment due to an AE are reported. The analysis population included all allocated participants who received at least 1 dose of study intervention.

End point type	Primary
----------------	---------

End point timeframe:

Up to approximately 24 months

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Per protocol, no statistical analysis was planned for this endpoint.

End point values	Cohort A Pembrolizumab /vibostolimab coformulation	Cohort B Pembrolizumab /vibostolimab coformulation	Cohort C Pembrolizumab /vibostolimab coformulation	Cohort D Pembrolizumab /vibostolimab coformulation
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	42	42	20	30
Units: Percentage of Participants				
number (not applicable)	19.0	4.8	15.0	13.3

End point values	Cohort E Pembrolizumab /vibostolimab coformulation	Cohort F Pembrolizumab /vibostolimab coformulation		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	25	32		
Units: Percentage of Participants				
number (not applicable)	4.0	12.5		

Statistical analyses

No statistical analyses for this end point

Secondary: Objective Response Rate (ORR) as assessed by Lugano 2014 Classification (Cohorts A-D & F)

End point title	Objective Response Rate (ORR) as assessed by Lugano 2014 Classification (Cohorts A-D & F)
End point description:	
ORR was assessed based on Lugano 2014 Classification. ORR is defined as the percentage of the participants who had complete response (CR) or partial response (PR) and was evaluated using computed tomography (CT) and positron emission tomography (PET)-CT. CR is complete metabolic (no/minimal fluorodeoxyglucose [FDG] uptake) and radiologic response (target lesions regress to ≤ 5 cm in longest transverse diameter of a lesion) and no new lesions. PR is partial metabolic (moderate/high FDG uptake) and radiologic response ($\geq 50\%$ decrease in sum of product diameters for multiple lesions of up to 6 target measurable nodes and extranodal sites, no increase in lesions, and spleen regressed by $>50\%$ in length beyond normal). ORR for Cohorts A-D and F is presented. Cohort E is presented separately. The analysis population consisted of all participants who have received at least one dose of study intervention and had ORR measured by Lugano 2014 Classification	
End point type	Secondary
End point timeframe:	
Up to approximately 37 months	

End point values	Cohort A Pembrolizumab /vibostolimab coformulation	Cohort B Pembrolizumab /vibostolimab coformulation	Cohort C Pembrolizumab /vibostolimab coformulation	Cohort D Pembrolizumab /vibostolimab coformulation
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	42	42	20	30
Units: Percentage of Participants				
number (confidence interval 95%)	64.3 (48.0 to 78.4)	35.7 (21.6 to 52.0)	15.0 (3.2 to 37.9)	16.7 (5.6 to 34.7)

End point values	Cohort E Pembrolizumab /vibostolimab coformulation	Cohort F Pembrolizumab /vibostolimab coformulation		
------------------	---	---	--	--

Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[4]	32		
Units: Percentage of Participants				
number (confidence interval 95%)	(to)	18.8 (7.2 to 36.4)		

Notes:

[4] - ORR for Cohort E is evaluated using IMWG Criteria and is presented separately.

Statistical analyses

No statistical analyses for this end point

Secondary: Objective Response Rate (ORR) as assessed by the 2016 International Myeloma Working Group (IMWG) Response Criteria (Cohort E)

End point title	Objective Response Rate (ORR) as assessed by the 2016 International Myeloma Working Group (IMWG) Response Criteria (Cohort E)
-----------------	---

End point description:

ORR is the percentage of the participants with either a stringent complete response (sCR), CR, very good partial response (VGPR), or PR according to the IMWG Response Criteria. CR = negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND <5% plasmacytomas in the bone marrow; sCR=stringent complete response, CR as above PLUS normal serum free light-chain (FLC) assay ratio and absence of clonal cells in bone marrow; VGPR = serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M-component <100 mg/24 hr; PR = ≥50% reduction of serum Mprotein and reduction in 24-hour urinary M-protein by ≥90% or to <200 mg/24 hours. ORR for Cohorts A-D and F were presented in a previous outcome measure. The analysis population included all participants who have received at least one dose of study intervention and had ORR measured by 2016 IMWG Response Criteria.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to approximately 37 months

End point values	Cohort A Pembrolizumab /vibostolimab coformulation	Cohort B Pembrolizumab /vibostolimab coformulation	Cohort C Pembrolizumab /vibostolimab coformulation	Cohort D Pembrolizumab /vibostolimab coformulation
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[5]	0 ^[6]	0 ^[7]	0 ^[8]
Units: Percentage of Participants				
number (confidence interval 95%)	(to)	(to)	(to)	(to)

Notes:

[5] - ORR for Cohorts A-D & F is evaluated using IWGC Lugano Classification and is presented separately.

[6] - ORR for Cohorts A-D & F is evaluated using IWGC Lugano Classification and is presented separately.

[7] - ORR for Cohorts A-D & F is evaluated using IWGC Lugano Classification and is presented separately.

[8] - ORR for Cohorts A-D & F is evaluated using IWGC Lugano Classification and is presented separately.

End point values	Cohort E Pembrolizumab /vibostolimab coformulation	Cohort F Pembrolizumab /vibostolimab coformulation		
------------------	---	---	--	--

Subject group type	Reporting group	Reporting group		
Number of subjects analysed	25	0 ^[9]		
Units: Percentage of Participants				
number (confidence interval 95%)	0.0 (0.0 to 13.7)	(to)		

Notes:

[9] - ORR for Cohorts A-D & F is evaluated using IWGC Lugano Classification and is presented separately.

Statistical analyses

No statistical analyses for this end point

Secondary: Duration of Response (DOR) as assessed by Lugano 2014 Classification (Cohorts A-D & F)

End point title	Duration of Response (DOR) as assessed by Lugano 2014 Classification (Cohorts A-D & F)
-----------------	--

End point description:

For participants who demonstrate a confirmed CR or PR, DOR is defined as the time from CR or PR to documented disease progression or death. Participants are assessed using CT and PET-CT and response was evaluated based on the Lugano 2014 Classification. CR is complete metabolic (no/minimal FDG uptake) and radiologic response (target lesions regress to ≤ 5 cm in longest transverse diameter of a lesion) and no new lesions. PR is partial metabolic (moderate/high FDG uptake) and radiologic response ($\geq 50\%$ decrease in sum of product diameters (SPD) for multiple lesions of up to 6 target measurable nodes and extranodal sites, no increase in lesions, and spleen regressed by $>50\%$ in length beyond normal). DOR for Cohorts A-D and F is presented. Cohort E is presented separately. The analysis population included all participants who have received at least one dose of study intervention and had a response measured by measured by Lugano 2014 Classification

End point type	Secondary
----------------	-----------

End point timeframe:

Up to approximately 37 months

End point values	Cohort A Pembrolizumab /vibostolimab coformulation	Cohort B Pembrolizumab /vibostolimab coformulation	Cohort C Pembrolizumab /vibostolimab coformulation	Cohort D Pembrolizumab /vibostolimab coformulation
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	27	15	3	5
Units: Months				
median (confidence interval 95%)	5.4 (2.9 to 11.00)	3.0 (2.8 to 10.2)	2.8 (2.8 to 9999)	9999 (2.9 to 9999)

End point values	Cohort E Pembrolizumab /vibostolimab coformulation	Cohort F Pembrolizumab /vibostolimab coformulation		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[10]	6		
Units: Months				
median (confidence interval 95%)	(to)	3.4 (1.6 to 9999)		

Notes:

[10] - DOR for Cohort E is evaluated using IMWG criteria and is presented separately.

Statistical analyses

No statistical analyses for this end point

Secondary: Duration of Response (DOR) as assessed by 2016 IMWG Response Criteria (Cohort E)

End point title	Duration of Response (DOR) as assessed by 2016 IMWG Response Criteria (Cohort E)
-----------------	--

End point description:

DOR is defined as the time from CR or PR to documented disease progression or death. DOR for Cohort E was measured by the 2016 IMWG Response Criteria with response criteria defined as participants with either a sCR, CR, VGPR, or PR. CR = negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND <5% plasmacytomas in the bone marrow; sCR=CR as above PLUS normal serum FLC assay ratio and absence of clonal cells in bone marrow; VGPR = serum and urine M-component detectable by immunofixation but not on electrophoresis OR $\geq 90\%$ reduction in serum M-component plus urine M-component <100 mg/24 hr; PR = $\geq 50\%$ reduction of serum Mprotein and reduction in 24-hour urinary M-protein by $\geq 90\%$ or to <200 mg/24 hours. Cohorts A-D and F were presented in a previous outcome measure. The analysis population included all participants who have received at least one dose of study intervention and had a response measured by measured by 2016 IMWG Response Criteria.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to approximately 37 months

End point values	Cohort A Pembrolizumab /vibostolimab coformulation	Cohort B Pembrolizumab /vibostolimab coformulation	Cohort C Pembrolizumab /vibostolimab coformulation	Cohort D Pembrolizumab /vibostolimab coformulation
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[11]	0 ^[12]	0 ^[13]	0 ^[14]
Units: Months				
median (confidence interval 95%)	(to)	(to)	(to)	(to)

Notes:

[11] - DOR for Cohorts A-D & F is evaluated using IWGC Lugano Classification and is presented separately.

[12] - DOR for Cohorts A-D & F is evaluated using IWGC Lugano Classification and is presented separately.

[13] - DOR for Cohorts A-D & F is evaluated using IWGC Lugano Classification and is presented separately.

[14] - DOR for Cohorts A-D & F is evaluated using IWGC Lugano Classification and is presented separately.

End point values	Cohort E Pembrolizumab /vibostolimab coformulation	Cohort F Pembrolizumab /vibostolimab coformulation		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[15]	0 ^[16]		
Units: Months				

median (confidence interval 95%)	(to)	(to)		
----------------------------------	--------	--------	--	--

Notes:

[15] - Cohort E had no participants with a response.

[16] - DOR for Cohorts A-D & F is evaluated using IWGC Lugano Classification and is presented separately.

Statistical analyses

No statistical analyses for this end point

Secondary: Disease Control Rate (DCR) as Assessed by Lugano 2014 Classification (Cohorts A-D & F)

End point title	Disease Control Rate (DCR) as Assessed by Lugano 2014 Classification (Cohorts A-D & F)
End point description:	
DCR is % of participants who had tumor response per response criteria or have stable disease (SD) for ≥ 12 weeks before any evidence of progressive disease (PD). CR or PR were evaluated with CT and PET-CT. CR: complete metabolic (no/minimal FDG uptake) and radiologic response (target lesions regress to ≤ 5 cm in longest transverse diameter of a lesion) and no new lesions. PR: partial metabolic (moderate/high FDG uptake) and radiologic response ($\geq 50\%$ decrease in sum of product diameters for multiple lesions of up to 6 target measurable nodes and extranodal sites, no increase in lesions, and spleen regressed by $>50\%$ in length beyond normal). SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD: At least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm. Analysis population = all participants who have received at least 1 dose of study intervention and were evaluated using Lugano 2014 Classification.	
End point type	Secondary
End point timeframe:	
Up to approximately 37 months	

End point values	Cohort A Pembrolizumab /vibostolimab coformulation	Cohort B Pembrolizumab /vibostolimab coformulation	Cohort C Pembrolizumab /vibostolimab coformulation	Cohort D Pembrolizumab /vibostolimab coformulation
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	42	42	20	30
Units: Percentage of Participants				
number (confidence interval 95%)	73.8 (58.0 to 86.1)	59.5 (43.3 to 74.4)	25.0 (8.7 to 49.1)	16.7 (5.6 to 34.7)

End point values	Cohort E Pembrolizumab /vibostolimab coformulation	Cohort F Pembrolizumab /vibostolimab coformulation		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[17]	32		
Units: Percentage of Participants				
number (confidence interval 95%)	(to)	31.3 (16.1 to 50.0)		

Notes:

[17] - DCR for Cohort E is evaluated using IMWG criteria and is presented separately.

Statistical analyses

No statistical analyses for this end point

Secondary: Disease Control Rate (DCR) as Assessed by 2016 IMWG Response Criteria (Cohort E)

End point title	Disease Control Rate (DCR) as Assessed by 2016 IMWG Response Criteria (Cohort E)
End point description: DCR is % of participants who achieved tumor response or have SD for ≥ 12 weeks before any evidence of PD. Response criteria: either a sCR, CR, VGPR, or PR. CR: negative immunofixation of serum and urine & disappearance of any soft tissue plasmacytomas & $< 5\%$ plasmacytomas in the bone marrow; sCR: CR as above + normal serum FLC assay ratio and absence of clonal cells in bone marrow; VGPR: serum and urine M-component detectable by immunofixation but not on electrophoresis OR $\geq 90\%$ reduction in serum M-component plus urine M-component < 100 mg/24 hr; PR: $\geq 50\%$ reduction of serum Mprotein and reduction in 24-hour urinary M-protein by $\geq 90\%$ or to < 200 mg/24 hours. SD: Not meeting criteria for CR, VGPR, PR, or PD. PD as defined by prespecified 2016 IMWG response criteria. Cohorts A-D and F were presented in a previous outcome measure. Analysis population included all participants who have received at least one dose of study intervention and were evaluated using 2016 IMWG Response Criteria 2016.	
End point type	Secondary
End point timeframe: Up to approximately 37 months	

End point values	Cohort A Pembrolizumab /vibostolimab coformulation	Cohort B Pembrolizumab /vibostolimab coformulation	Cohort C Pembrolizumab /vibostolimab coformulation	Cohort D Pembrolizumab /vibostolimab coformulation
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[18]	0 ^[19]	0 ^[20]	0 ^[21]
Units: Percentage of Participants				
number (confidence interval 95%)	(to)	(to)	(to)	(to)

Notes:

[18] - DCR for Cohorts A-D & F is evaluated using IWGC Lugano Classification and is presented separately.

[19] - DCR for Cohorts A-D & F is evaluated using IWGC Lugano Classification and is presented separately.

[20] - DCR for Cohorts A-D & F is evaluated using IWGC Lugano Classification and is presented separately.

[21] - DCR for Cohorts A-D & F is evaluated using IWGC Lugano Classification and is presented separately.

End point values	Cohort E Pembrolizumab /vibostolimab coformulation	Cohort F Pembrolizumab /vibostolimab coformulation		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	25	0 ^[22]		
Units: Percentage of Participants				

number (confidence interval 95%)	16.0 (4.5 to 36.1)	(to)		
----------------------------------	--------------------	--------	--	--

Notes:

[22] - DCR for Cohorts A-D & F is evaluated using IWGC Lugano Classification and is presented separately.

Statistical analyses

No statistical analyses for this end point

Secondary: Lowest Plasma Concentration (Ctough) of Vibostolimab

End point title	Lowest Plasma Concentration (Ctough) of Vibostolimab
-----------------	--

End point description:

Ctough is the lowest concentration reached by a drug before the next dose is administered. Blood samples collected predose were used to determine Ctough of Vibostolimab. The analysis population included all participants who received at least one dose of intervention and had data for the corresponding cycle.

End point type	Secondary
----------------	-----------

End point timeframe:

Predose at Cycles 1, 3, 7, 11, 15, 19, 23, 27 and 31. Cycle = 3 weeks

End point values	Cohort A Pembrolizumab /vibostolimab coformulation	Cohort B Pembrolizumab /vibostolimab coformulation	Cohort C Pembrolizumab /vibostolimab coformulation	Cohort D Pembrolizumab /vibostolimab coformulation
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	35	40	18	18
Units: ug/mL				
geometric mean (confidence interval 95%)				
Cycle 1	8.06 (6.71 to 9.68)	9.86 (8.22 to 11.8)	10.0 (6.61 to 15.3)	9.64 (7.24 to 12.9)
Cycle 3	15.3 (12.4 to 18.8)	17.0 (13.3 to 21.6)	22.6 (13.5 to 38.0)	14.5 (7.55 to 27.9)
Cycle 7	21.0 (17.1 to 25.8)	19.5 (14.9 to 25.5)	38.1 (6.15 to 236)	25.8 (5.19 to 129)
Cycle 11	22.6 (16.6 to 30.8)	24.2 (16.3 to 35.8)	28.9 (0.251 to 3330)	40.7 (40.1 to 41.4)
Cycle 15	26.2 (17.0 to 40.6)	25.6 (17.4 to 37.8)	9999 (9999 to 9999)	40.6 (7.65 to 216)
Cycle 19	34.8 (21.6 to 56.2)	24.2 (13.8 to 42.6)	9999 (9999 to 9999)	31.1 (5.49 to 176)
Cycle 23	36.5 (24.2 to 55.2)	24.8 (15.2 to 40.3)	9999 (9999 to 9999)	51.5 (-9999 to 9999)
Cycle 27	40.6 (22.8 to 72.4)	19.3 (9.23 to 40.4)	9999 (9999 to 9999)	48.9 (8.42 to 284)
Cycle 31	31.7 (2.43 to 413)	31.6 (6.13 to 163)	9999 (9999 to 9999)	38.0 (1.57 to 923)

End point values	Cohort E Pembrolizumab	Cohort F Pembrolizumab		
------------------	---------------------------	---------------------------	--	--

	/vibostolimab coformulation	/vibostolimab coformulation		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	25	25		
Units: ug/mL				
geometric mean (confidence interval 95%)				
Cycle 1	9.86 (6.52 to 14.9)	9.52 (6.95 to 13.0)		
Cycle 3	17.9 (5.07 to 63.3)	20.2 (15.8 to 25.9)		
Cycle 7	9999 (9999 to 9999)	22.1 (14.1 to 34.7)		
Cycle 11	9999 (9999 to 9999)	9999 (9999 to 9999)		
Cycle 15	9999 (9999 to 9999)	9999 (9999 to 9999)		
Cycle 19	9999 (9999 to 9999)	9999 (9999 to 9999)		
Cycle 23	9999 (9999 to 9999)	9999 (9999 to 9999)		
Cycle 27	9999 (9999 to 9999)	9999 (9999 to 9999)		
Cycle 31	9999 (9999 to 9999)	9999 (9999 to 9999)		

Statistical analyses

No statistical analyses for this end point

Secondary: Maximum Concentration (Cmax) of Vibostolimab

End point title	Maximum Concentration (Cmax) of Vibostolimab
End point description:	
Cmax is the maximum concentration of the drug observed in plasma. Blood samples collected post dose were used to determine Cmax of Vibostolimab. The analysis population included all participants who received at least one dose of intervention and had data for the corresponding cycle.	
End point type	Secondary
End point timeframe:	
Postdose: after end of infusion (up to ~10 minutes) at Cycles 1 and 8. Cycle = 3 weeks	

End point values	Cohort A Pembrolizumab /vibostolimab coformulation	Cohort B Pembrolizumab /vibostolimab coformulation	Cohort C Pembrolizumab /vibostolimab coformulation	Cohort D Pembrolizumab /vibostolimab coformulation
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	37	38	17	26
Units: ug/mL				
geometric mean (confidence interval 95%)				
Cycle 1	85.8 (65.4 to 113)	85.4 (70.0 to 104)	42.6 (35.2 to 51.5)	64.2 (54.2 to 76.1)

Cycle 8	84.8 (69.9 to 103)	75.8 (61.5 to 93.5)	112 (22.8 to 552)	77.4 (46.4 to 129)
---------	--------------------	---------------------	-------------------	--------------------

End point values	Cohort E Pembrolizumab /vibostolimab coformulation	Cohort F Pembrolizumab /vibostolimab coformulation		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	24	28		
Units: ug/mL				
geometric mean (confidence interval 95%)				
Cycle 1	53.2 (45.7 to 61.9)	55.2 (44.2 to 69.0)		
Cycle 8	9999 (9999 to 9999)	80.9 (58.4 to 112)		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Up to ~37 months.

Adverse event reporting additional description:

All-cause mortality: All allocated participants. Safety: All allocated participants who received at least 1 dose of study intervention. Per protocol, MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" and "Disease progression" not related to study drug are excluded as AEs.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	27.1
--------------------	------

Reporting groups

Reporting group title	COHORT A
-----------------------	----------

Reporting group description:

Participants with classic Hodgkin's lymphoma (cHL) or primary mediastinal Bcell lymphoma (PMBCL) who are relapsed or refractory to at least 1 line of prior therapy (cHL) or at least 2 lines of prior therapies (PMBCL) received pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous IV infusion once every 3 weeks (Q3W) for up to 35 cycles up to approximately 2 years.

Reporting group title	COHORT B
-----------------------	----------

Reporting group description:

Participants with cHL or PMBCL who are relapsed or refractory to at least 2 lines of prior therapies (cHL) or at least 3 lines of prior therapies (PMBCL) received pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous IV infusion once every 3 weeks (Q3W) for up to 35 cycles up to approximately 2 years.

Reporting group title	COHORT E
-----------------------	----------

Reporting group description:

Participants with relapsed or refractory multiple myeloma (MM) following at least 3 lines of therapy and have exhausted all approved lines of therapy received pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous IV infusion once every 3 weeks (Q3W) for up to 35 cycles up to approximately 2 years.

Reporting group title	COHORT D
-----------------------	----------

Reporting group description:

Participants with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) following at least 2 lines of therapy received pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous IV infusion once every 3 weeks (Q3W) for up to 35 cycles up to approximately 2 years.

Reporting group title	COHORT F
-----------------------	----------

Reporting group description:

Participants with relapsed or refractory non-Hodgkin's lymphoma (NHL) following at least 2 lines of therapy received pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous IV infusion once every 3 weeks (Q3W) for up to 35 cycles up to approximately 2 years.

Reporting group title	COHORT C
-----------------------	----------

Reporting group description:

Participants with relapsed or refractory follicular lymphoma (FL) following at least 2 lines of therapy received pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous IV infusion once every 3 weeks (Q3W) for up to 35 cycles up to approximately 2 years.

Serious adverse events	COHORT A	COHORT B	COHORT E
Total subjects affected by serious adverse events			
subjects affected / exposed	17 / 42 (40.48%)	11 / 42 (26.19%)	8 / 25 (32.00%)
number of deaths (all causes)	14	10	14
number of deaths resulting from adverse events	2	2	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
High-grade B-cell lymphoma			
subjects affected / exposed	0 / 42 (0.00%)	1 / 42 (2.38%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Leydig cell tumour of the testis			
subjects affected / exposed	0 / 42 (0.00%)	0 / 42 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma			
subjects affected / exposed	0 / 42 (0.00%)	0 / 42 (0.00%)	1 / 25 (4.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Embolism			
subjects affected / exposed	0 / 42 (0.00%)	0 / 42 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 42 (0.00%)	0 / 42 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	0 / 42 (0.00%)	0 / 42 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Infusion related hypersensitivity reaction			

subjects affected / exposed	0 / 42 (0.00%)	1 / 42 (2.38%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cytokine release syndrome			
subjects affected / exposed	1 / 42 (2.38%)	0 / 42 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Benign prostatic hyperplasia			
subjects affected / exposed	1 / 42 (2.38%)	0 / 42 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	0 / 42 (0.00%)	0 / 42 (0.00%)	1 / 25 (4.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophagobronchial fistula			
subjects affected / exposed	0 / 42 (0.00%)	0 / 42 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonitis			
subjects affected / exposed	2 / 42 (4.76%)	0 / 42 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	2 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	0 / 42 (0.00%)	0 / 42 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Platelet count decreased			

subjects affected / exposed	0 / 42 (0.00%)	0 / 42 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Limb injury			
subjects affected / exposed	0 / 42 (0.00%)	1 / 42 (2.38%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital, familial and genetic disorders			
Tracheo-oesophageal fistula			
subjects affected / exposed	0 / 42 (0.00%)	0 / 42 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyloric stenosis			
subjects affected / exposed	1 / 42 (2.38%)	0 / 42 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute cardiac event			
subjects affected / exposed	0 / 42 (0.00%)	0 / 42 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arrhythmia			
subjects affected / exposed	0 / 42 (0.00%)	0 / 42 (0.00%)	1 / 25 (4.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocarditis			
subjects affected / exposed	1 / 42 (2.38%)	0 / 42 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure acute			

subjects affected / exposed	0 / 42 (0.00%)	0 / 42 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial fibrillation			
subjects affected / exposed	0 / 42 (0.00%)	1 / 42 (2.38%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Seizure			
subjects affected / exposed	1 / 42 (2.38%)	0 / 42 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neurotoxicity			
subjects affected / exposed	0 / 42 (0.00%)	0 / 42 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neurological symptom			
subjects affected / exposed	0 / 42 (0.00%)	0 / 42 (0.00%)	1 / 25 (4.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Febrile neutropenia			
subjects affected / exposed	0 / 42 (0.00%)	1 / 42 (2.38%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anaemia			
subjects affected / exposed	0 / 42 (0.00%)	0 / 42 (0.00%)	1 / 25 (4.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphadenopathy			
subjects affected / exposed	1 / 42 (2.38%)	0 / 42 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutropenia			

subjects affected / exposed	0 / 42 (0.00%)	0 / 42 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			
subjects affected / exposed	0 / 42 (0.00%)	0 / 42 (0.00%)	1 / 25 (4.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 42 (0.00%)	0 / 42 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspepsia			
subjects affected / exposed	1 / 42 (2.38%)	0 / 42 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	0 / 42 (0.00%)	0 / 42 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric haemorrhage			
subjects affected / exposed	1 / 42 (2.38%)	0 / 42 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune-mediated gastritis			
subjects affected / exposed	1 / 42 (2.38%)	0 / 42 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileus			
subjects affected / exposed	0 / 42 (0.00%)	0 / 42 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal haemorrhage			

subjects affected / exposed	0 / 42 (0.00%)	0 / 42 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	0 / 42 (0.00%)	0 / 42 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholecystitis			
subjects affected / exposed	0 / 42 (0.00%)	1 / 42 (2.38%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Toxic epidermal necrolysis			
subjects affected / exposed	0 / 42 (0.00%)	0 / 42 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Drug eruption			
subjects affected / exposed	0 / 42 (0.00%)	1 / 42 (2.38%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rash			
subjects affected / exposed	0 / 42 (0.00%)	0 / 42 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urticaria			
subjects affected / exposed	1 / 42 (2.38%)	1 / 42 (2.38%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 42 (0.00%)	0 / 42 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Hydronephrosis			
subjects affected / exposed	0 / 42 (0.00%)	0 / 42 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nephritis			
subjects affected / exposed	1 / 42 (2.38%)	0 / 42 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure			
subjects affected / exposed	0 / 42 (0.00%)	0 / 42 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary retention			
subjects affected / exposed	1 / 42 (2.38%)	0 / 42 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
Thyroiditis			
subjects affected / exposed	1 / 42 (2.38%)	0 / 42 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Muscular weakness			
subjects affected / exposed	0 / 42 (0.00%)	0 / 42 (0.00%)	1 / 25 (4.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myositis			
subjects affected / exposed	0 / 42 (0.00%)	0 / 42 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Acute hepatitis B			

subjects affected / exposed	0 / 42 (0.00%)	0 / 42 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aspergillus infection			
subjects affected / exposed	0 / 42 (0.00%)	1 / 42 (2.38%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19			
subjects affected / exposed	1 / 42 (2.38%)	1 / 42 (2.38%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19 pneumonia			
subjects affected / exposed	1 / 42 (2.38%)	0 / 42 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	0 / 42 (0.00%)	0 / 42 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Encephalitis			
subjects affected / exposed	2 / 42 (4.76%)	0 / 42 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection			
subjects affected / exposed	1 / 42 (2.38%)	0 / 42 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 42 (0.00%)	0 / 42 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection			

subjects affected / exposed	0 / 42 (0.00%)	0 / 42 (0.00%)	1 / 25 (4.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Parainfluenzae virus infection			
subjects affected / exposed	0 / 42 (0.00%)	0 / 42 (0.00%)	1 / 25 (4.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	1 / 42 (2.38%)	2 / 42 (4.76%)	2 / 25 (8.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
Post-acute COVID-19 syndrome			
subjects affected / exposed	1 / 42 (2.38%)	0 / 42 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			
subjects affected / exposed	0 / 42 (0.00%)	0 / 42 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 42 (0.00%)	0 / 42 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Soft tissue infection			
subjects affected / exposed	0 / 42 (0.00%)	0 / 42 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	0 / 42 (0.00%)	0 / 42 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound infection			

subjects affected / exposed	0 / 42 (0.00%)	0 / 42 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular device infection			
subjects affected / exposed	1 / 42 (2.38%)	0 / 42 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 42 (0.00%)	0 / 42 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypercalcaemia			
subjects affected / exposed	0 / 42 (0.00%)	0 / 42 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	COHORT D	COHORT F	COHORT C
Total subjects affected by serious adverse events			
subjects affected / exposed	11 / 30 (36.67%)	13 / 32 (40.63%)	8 / 20 (40.00%)
number of deaths (all causes)	24	15	9
number of deaths resulting from adverse events	4	3	2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
High-grade B-cell lymphoma			
subjects affected / exposed	0 / 30 (0.00%)	0 / 32 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leydig cell tumour of the testis			
subjects affected / exposed	0 / 30 (0.00%)	1 / 32 (3.13%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma			

subjects affected / exposed	0 / 30 (0.00%)	0 / 32 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Embolism			
subjects affected / exposed	1 / 30 (3.33%)	0 / 32 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 30 (0.00%)	1 / 32 (3.13%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	0 / 30 (0.00%)	0 / 32 (0.00%)	1 / 20 (5.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Infusion related hypersensitivity reaction			
subjects affected / exposed	0 / 30 (0.00%)	0 / 32 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cytokine release syndrome			
subjects affected / exposed	0 / 30 (0.00%)	0 / 32 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Benign prostatic hyperplasia			
subjects affected / exposed	0 / 30 (0.00%)	0 / 32 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			

subjects affected / exposed	0 / 30 (0.00%)	0 / 32 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophagobronchial fistula			
subjects affected / exposed	0 / 30 (0.00%)	1 / 32 (3.13%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonitis			
subjects affected / exposed	0 / 30 (0.00%)	0 / 32 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	0 / 30 (0.00%)	0 / 32 (0.00%)	1 / 20 (5.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Investigations			
Platelet count decreased			
subjects affected / exposed	1 / 30 (3.33%)	0 / 32 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Limb injury			
subjects affected / exposed	0 / 30 (0.00%)	0 / 32 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital, familial and genetic disorders			
Tracheo-oesophageal fistula			
subjects affected / exposed	0 / 30 (0.00%)	1 / 32 (3.13%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyloric stenosis			

subjects affected / exposed	0 / 30 (0.00%)	0 / 32 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute cardiac event			
subjects affected / exposed	1 / 30 (3.33%)	0 / 32 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Arrhythmia			
subjects affected / exposed	0 / 30 (0.00%)	0 / 32 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocarditis			
subjects affected / exposed	0 / 30 (0.00%)	0 / 32 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure acute			
subjects affected / exposed	0 / 30 (0.00%)	1 / 32 (3.13%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial fibrillation			
subjects affected / exposed	1 / 30 (3.33%)	0 / 32 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Seizure			
subjects affected / exposed	0 / 30 (0.00%)	0 / 32 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neurotoxicity			
subjects affected / exposed	0 / 30 (0.00%)	1 / 32 (3.13%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neurological symptom			

subjects affected / exposed	0 / 30 (0.00%)	0 / 32 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Febrile neutropenia			
subjects affected / exposed	0 / 30 (0.00%)	0 / 32 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anaemia			
subjects affected / exposed	0 / 30 (0.00%)	0 / 32 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphadenopathy			
subjects affected / exposed	0 / 30 (0.00%)	0 / 32 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutropenia			
subjects affected / exposed	1 / 30 (3.33%)	0 / 32 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	2 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			
subjects affected / exposed	0 / 30 (0.00%)	1 / 32 (3.13%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 30 (0.00%)	1 / 32 (3.13%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspepsia			
subjects affected / exposed	0 / 30 (0.00%)	0 / 32 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			

subjects affected / exposed	0 / 30 (0.00%)	1 / 32 (3.13%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric haemorrhage			
subjects affected / exposed	0 / 30 (0.00%)	0 / 32 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune-mediated gastritis			
subjects affected / exposed	0 / 30 (0.00%)	0 / 32 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileus			
subjects affected / exposed	0 / 30 (0.00%)	1 / 32 (3.13%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal haemorrhage			
subjects affected / exposed	0 / 30 (0.00%)	1 / 32 (3.13%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Nausea			
subjects affected / exposed	0 / 30 (0.00%)	1 / 32 (3.13%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholecystitis			
subjects affected / exposed	0 / 30 (0.00%)	0 / 32 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Toxic epidermal necrolysis			
subjects affected / exposed	1 / 30 (3.33%)	0 / 32 (0.00%)	1 / 20 (5.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Drug eruption			

subjects affected / exposed	0 / 30 (0.00%)	0 / 32 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rash			
subjects affected / exposed	1 / 30 (3.33%)	0 / 32 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urticaria			
subjects affected / exposed	1 / 30 (3.33%)	0 / 32 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	1 / 30 (3.33%)	2 / 32 (6.25%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hydronephrosis			
subjects affected / exposed	0 / 30 (0.00%)	1 / 32 (3.13%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nephritis			
subjects affected / exposed	0 / 30 (0.00%)	0 / 32 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure			
subjects affected / exposed	0 / 30 (0.00%)	0 / 32 (0.00%)	1 / 20 (5.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary retention			
subjects affected / exposed	0 / 30 (0.00%)	0 / 32 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			

Thyroiditis			
subjects affected / exposed	0 / 30 (0.00%)	0 / 32 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Muscular weakness			
subjects affected / exposed	0 / 30 (0.00%)	0 / 32 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myositis			
subjects affected / exposed	0 / 30 (0.00%)	0 / 32 (0.00%)	1 / 20 (5.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Acute hepatitis B			
subjects affected / exposed	0 / 30 (0.00%)	1 / 32 (3.13%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aspergillus infection			
subjects affected / exposed	0 / 30 (0.00%)	0 / 32 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19			
subjects affected / exposed	0 / 30 (0.00%)	1 / 32 (3.13%)	2 / 20 (10.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19 pneumonia			
subjects affected / exposed	1 / 30 (3.33%)	1 / 32 (3.13%)	1 / 20 (5.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Cellulitis			
subjects affected / exposed	1 / 30 (3.33%)	0 / 32 (0.00%)	1 / 20 (5.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Encephalitis			
subjects affected / exposed	0 / 30 (0.00%)	0 / 32 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection			
subjects affected / exposed	0 / 30 (0.00%)	1 / 32 (3.13%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 30 (0.00%)	1 / 32 (3.13%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection			
subjects affected / exposed	0 / 30 (0.00%)	0 / 32 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Parainfluenzae virus infection			
subjects affected / exposed	0 / 30 (0.00%)	1 / 32 (3.13%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 30 (0.00%)	2 / 32 (6.25%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Post-acute COVID-19 syndrome			
subjects affected / exposed	0 / 30 (0.00%)	0 / 32 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			
subjects affected / exposed	1 / 30 (3.33%)	0 / 32 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			

subjects affected / exposed	1 / 30 (3.33%)	1 / 32 (3.13%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Soft tissue infection			
subjects affected / exposed	0 / 30 (0.00%)	1 / 32 (3.13%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	1 / 30 (3.33%)	0 / 32 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Wound infection			
subjects affected / exposed	1 / 30 (3.33%)	0 / 32 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular device infection			
subjects affected / exposed	0 / 30 (0.00%)	0 / 32 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 30 (0.00%)	1 / 32 (3.13%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypercalcaemia			
subjects affected / exposed	2 / 30 (6.67%)	0 / 32 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	COHORT A	COHORT B	COHORT E
Total subjects affected by non-serious adverse events subjects affected / exposed	35 / 42 (83.33%)	39 / 42 (92.86%)	16 / 25 (64.00%)
Vascular disorders Hypertension subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0	1 / 42 (2.38%) 1	1 / 25 (4.00%) 3
General disorders and administration site conditions Chills subjects affected / exposed occurrences (all) Hyperthermia subjects affected / exposed occurrences (all) Fatigue subjects affected / exposed occurrences (all) Influenza like illness subjects affected / exposed occurrences (all) Pyrexia subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1 3 / 42 (7.14%) 3 3 / 42 (7.14%) 3 3 / 42 (7.14%) 4 8 / 42 (19.05%) 8	4 / 42 (9.52%) 4 0 / 42 (0.00%) 0 6 / 42 (14.29%) 6 0 / 42 (0.00%) 0 7 / 42 (16.67%) 10	1 / 25 (4.00%) 1 0 / 25 (0.00%) 0 4 / 25 (16.00%) 4 0 / 25 (0.00%) 0 3 / 25 (12.00%) 4
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all) Pneumonitis subjects affected / exposed occurrences (all) Rhinorrhoea subjects affected / exposed occurrences (all) Upper-airway cough syndrome subjects affected / exposed occurrences (all)	4 / 42 (9.52%) 4 3 / 42 (7.14%) 5 1 / 42 (2.38%) 1 0 / 42 (0.00%) 0	2 / 42 (4.76%) 2 0 / 42 (0.00%) 0 0 / 42 (0.00%) 0 0 / 42 (0.00%) 0	2 / 25 (8.00%) 2 0 / 25 (0.00%) 0 1 / 25 (4.00%) 1 3 / 25 (12.00%) 3

Psychiatric disorders			
Insomnia			
subjects affected / exposed	4 / 42 (9.52%)	1 / 42 (2.38%)	1 / 25 (4.00%)
occurrences (all)	4	1	1
Investigations			
Aspartate aminotransferase increased			
subjects affected / exposed	5 / 42 (11.90%)	3 / 42 (7.14%)	1 / 25 (4.00%)
occurrences (all)	6	3	1
Alanine aminotransferase increased			
subjects affected / exposed	5 / 42 (11.90%)	3 / 42 (7.14%)	2 / 25 (8.00%)
occurrences (all)	5	3	2
Blood thyroid stimulating hormone increased			
subjects affected / exposed	3 / 42 (7.14%)	1 / 42 (2.38%)	1 / 25 (4.00%)
occurrences (all)	5	1	1
Blood creatinine increased			
subjects affected / exposed	0 / 42 (0.00%)	0 / 42 (0.00%)	4 / 25 (16.00%)
occurrences (all)	0	0	4
Blood bilirubin increased			
subjects affected / exposed	2 / 42 (4.76%)	0 / 42 (0.00%)	0 / 25 (0.00%)
occurrences (all)	5	0	0
Blood alkaline phosphatase increased			
subjects affected / exposed	1 / 42 (2.38%)	0 / 42 (0.00%)	3 / 25 (12.00%)
occurrences (all)	1	0	3
C-reactive protein increased			
subjects affected / exposed	0 / 42 (0.00%)	0 / 42 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Neutrophil count decreased			
subjects affected / exposed	1 / 42 (2.38%)	0 / 42 (0.00%)	0 / 25 (0.00%)
occurrences (all)	5	0	0
Lymphocyte count decreased			
subjects affected / exposed	1 / 42 (2.38%)	0 / 42 (0.00%)	3 / 25 (12.00%)
occurrences (all)	1	0	4
Weight decreased			
subjects affected / exposed	4 / 42 (9.52%)	0 / 42 (0.00%)	1 / 25 (4.00%)
occurrences (all)	4	0	1
Platelet count decreased			

subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0	3 / 42 (7.14%) 3	1 / 25 (4.00%) 1
Injury, poisoning and procedural complications Infusion related reaction subjects affected / exposed occurrences (all)	3 / 42 (7.14%) 3	2 / 42 (4.76%) 3	1 / 25 (4.00%) 1
Cardiac disorders Sinus tachycardia subjects affected / exposed occurrences (all)	2 / 42 (4.76%) 2	0 / 42 (0.00%) 0	2 / 25 (8.00%) 4
Nervous system disorders Headache subjects affected / exposed occurrences (all) Dizziness subjects affected / exposed occurrences (all)	3 / 42 (7.14%) 4 0 / 42 (0.00%) 0	4 / 42 (9.52%) 4 0 / 42 (0.00%) 0	0 / 25 (0.00%) 0 2 / 25 (8.00%) 2
Blood and lymphatic system disorders Eosinophilia subjects affected / exposed occurrences (all) Neutropenia subjects affected / exposed occurrences (all) Thrombocytopenia subjects affected / exposed occurrences (all) Anaemia subjects affected / exposed occurrences (all)	3 / 42 (7.14%) 3 4 / 42 (9.52%) 8 1 / 42 (2.38%) 3 5 / 42 (11.90%) 7	1 / 42 (2.38%) 1 0 / 42 (0.00%) 0 0 / 42 (0.00%) 0 5 / 42 (11.90%) 6	2 / 25 (8.00%) 2 1 / 25 (4.00%) 1 3 / 25 (12.00%) 3 7 / 25 (28.00%) 8
Gastrointestinal disorders Diarrhoea subjects affected / exposed occurrences (all) Nausea	7 / 42 (16.67%) 7	4 / 42 (9.52%) 5	0 / 25 (0.00%) 0

subjects affected / exposed occurrences (all)	4 / 42 (9.52%) 4	1 / 42 (2.38%) 1	2 / 25 (8.00%) 2
Vomiting subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1	0 / 42 (0.00%) 0	1 / 25 (4.00%) 1
Constipation subjects affected / exposed occurrences (all)	2 / 42 (4.76%) 2	2 / 42 (4.76%) 2	1 / 25 (4.00%) 2
Abdominal pain upper subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0	1 / 42 (2.38%) 1	0 / 25 (0.00%) 0
Skin and subcutaneous tissue disorders			
Rash subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1	5 / 42 (11.90%) 5	0 / 25 (0.00%) 0
Eczema subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1	3 / 42 (7.14%) 3	0 / 25 (0.00%) 0
Pruritus subjects affected / exposed occurrences (all)	13 / 42 (30.95%) 14	8 / 42 (19.05%) 13	1 / 25 (4.00%) 1
Rash maculo-papular subjects affected / exposed occurrences (all)	2 / 42 (4.76%) 2	2 / 42 (4.76%) 2	0 / 25 (0.00%) 0
Endocrine disorders			
Hypothyroidism subjects affected / exposed occurrences (all)	8 / 42 (19.05%) 13	3 / 42 (7.14%) 3	0 / 25 (0.00%) 0
Musculoskeletal and connective tissue disorders			
Muscle spasms subjects affected / exposed occurrences (all)	4 / 42 (9.52%) 4	0 / 42 (0.00%) 0	0 / 25 (0.00%) 0
Bone pain subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0	0 / 42 (0.00%) 0	2 / 25 (8.00%) 2
Back pain			

subjects affected / exposed occurrences (all)	2 / 42 (4.76%) 3	2 / 42 (4.76%) 2	2 / 25 (8.00%) 2
Arthralgia subjects affected / exposed occurrences (all)	3 / 42 (7.14%) 3	2 / 42 (4.76%) 3	2 / 25 (8.00%) 3
Muscular weakness subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0	0 / 42 (0.00%) 0	2 / 25 (8.00%) 2
Infections and infestations			
COVID-19 subjects affected / exposed occurrences (all)	4 / 42 (9.52%) 4	7 / 42 (16.67%) 8	0 / 25 (0.00%) 0
Pneumonia subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1	3 / 42 (7.14%) 3	0 / 25 (0.00%) 0
Urinary tract infection subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0	0 / 42 (0.00%) 0	2 / 25 (8.00%) 2
Upper respiratory tract infection subjects affected / exposed occurrences (all)	6 / 42 (14.29%) 7	3 / 42 (7.14%) 3	3 / 25 (12.00%) 5
Metabolism and nutrition disorders			
Hypercalcaemia subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0	1 / 42 (2.38%) 3	4 / 25 (16.00%) 4
Decreased appetite subjects affected / exposed occurrences (all)	2 / 42 (4.76%) 3	2 / 42 (4.76%) 2	4 / 25 (16.00%) 4
Hyperglycaemia subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0	0 / 42 (0.00%) 0	1 / 25 (4.00%) 2
Hypernatraemia subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0	0 / 42 (0.00%) 0	2 / 25 (8.00%) 2
Hyperuricaemia			

subjects affected / exposed	0 / 42 (0.00%)	0 / 42 (0.00%)	3 / 25 (12.00%)
occurrences (all)	0	0	3
Hypokalaemia			
subjects affected / exposed	1 / 42 (2.38%)	4 / 42 (9.52%)	0 / 25 (0.00%)
occurrences (all)	2	5	0

Non-serious adverse events	COHORT D	COHORT F	COHORT C
Total subjects affected by non-serious adverse events			
subjects affected / exposed	21 / 30 (70.00%)	24 / 32 (75.00%)	15 / 20 (75.00%)
Vascular disorders			
Hypertension			
subjects affected / exposed	1 / 30 (3.33%)	2 / 32 (6.25%)	1 / 20 (5.00%)
occurrences (all)	1	2	1
General disorders and administration site conditions			
Chills			
subjects affected / exposed	0 / 30 (0.00%)	0 / 32 (0.00%)	2 / 20 (10.00%)
occurrences (all)	0	0	2
Hyperthermia			
subjects affected / exposed	0 / 30 (0.00%)	0 / 32 (0.00%)	0 / 20 (0.00%)
occurrences (all)	0	0	0
Fatigue			
subjects affected / exposed	2 / 30 (6.67%)	0 / 32 (0.00%)	1 / 20 (5.00%)
occurrences (all)	2	0	1
Influenza like illness			
subjects affected / exposed	0 / 30 (0.00%)	0 / 32 (0.00%)	0 / 20 (0.00%)
occurrences (all)	0	0	0
Pyrexia			
subjects affected / exposed	4 / 30 (13.33%)	4 / 32 (12.50%)	0 / 20 (0.00%)
occurrences (all)	8	6	0
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	1 / 30 (3.33%)	4 / 32 (12.50%)	1 / 20 (5.00%)
occurrences (all)	1	4	1
Pneumonitis			
subjects affected / exposed	0 / 30 (0.00%)	1 / 32 (3.13%)	0 / 20 (0.00%)
occurrences (all)	0	1	0

Rhinorrhoea			
subjects affected / exposed	0 / 30 (0.00%)	2 / 32 (6.25%)	0 / 20 (0.00%)
occurrences (all)	0	2	0
Upper-airway cough syndrome			
subjects affected / exposed	0 / 30 (0.00%)	0 / 32 (0.00%)	0 / 20 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Insomnia			
subjects affected / exposed	0 / 30 (0.00%)	0 / 32 (0.00%)	0 / 20 (0.00%)
occurrences (all)	0	0	0
Investigations			
Aspartate aminotransferase increased			
subjects affected / exposed	2 / 30 (6.67%)	1 / 32 (3.13%)	0 / 20 (0.00%)
occurrences (all)	2	2	0
Alanine aminotransferase increased			
subjects affected / exposed	2 / 30 (6.67%)	1 / 32 (3.13%)	0 / 20 (0.00%)
occurrences (all)	4	1	0
Blood thyroid stimulating hormone increased			
subjects affected / exposed	0 / 30 (0.00%)	4 / 32 (12.50%)	1 / 20 (5.00%)
occurrences (all)	0	4	1
Blood creatinine increased			
subjects affected / exposed	3 / 30 (10.00%)	2 / 32 (6.25%)	1 / 20 (5.00%)
occurrences (all)	3	2	1
Blood bilirubin increased			
subjects affected / exposed	0 / 30 (0.00%)	2 / 32 (6.25%)	0 / 20 (0.00%)
occurrences (all)	0	2	0
Blood alkaline phosphatase increased			
subjects affected / exposed	1 / 30 (3.33%)	0 / 32 (0.00%)	0 / 20 (0.00%)
occurrences (all)	1	0	0
C-reactive protein increased			
subjects affected / exposed	1 / 30 (3.33%)	2 / 32 (6.25%)	0 / 20 (0.00%)
occurrences (all)	1	2	0
Neutrophil count decreased			
subjects affected / exposed	2 / 30 (6.67%)	0 / 32 (0.00%)	0 / 20 (0.00%)
occurrences (all)	2	0	0
Lymphocyte count decreased			

subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	0 / 32 (0.00%) 0	0 / 20 (0.00%) 0
Weight decreased subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	0 / 32 (0.00%) 0	0 / 20 (0.00%) 0
Platelet count decreased subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	0 / 32 (0.00%) 0	2 / 20 (10.00%) 2
Injury, poisoning and procedural complications Infusion related reaction subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	1 / 32 (3.13%) 1	0 / 20 (0.00%) 0
Cardiac disorders Sinus tachycardia subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	0 / 32 (0.00%) 0	0 / 20 (0.00%) 0
Nervous system disorders Headache subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	1 / 32 (3.13%) 1	1 / 20 (5.00%) 1
Dizziness subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	1 / 32 (3.13%) 1	0 / 20 (0.00%) 0
Blood and lymphatic system disorders Eosinophilia subjects affected / exposed occurrences (all)	1 / 30 (3.33%) 1	0 / 32 (0.00%) 0	0 / 20 (0.00%) 0
Neutropenia subjects affected / exposed occurrences (all)	4 / 30 (13.33%) 4	5 / 32 (15.63%) 5	3 / 20 (15.00%) 3
Thrombocytopenia subjects affected / exposed occurrences (all)	2 / 30 (6.67%) 3	4 / 32 (12.50%) 4	1 / 20 (5.00%) 1
Anaemia subjects affected / exposed occurrences (all)	5 / 30 (16.67%) 5	4 / 32 (12.50%) 5	1 / 20 (5.00%) 1

Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	4 / 30 (13.33%)	3 / 32 (9.38%)	0 / 20 (0.00%)
occurrences (all)	4	3	0
Nausea			
subjects affected / exposed	0 / 30 (0.00%)	5 / 32 (15.63%)	2 / 20 (10.00%)
occurrences (all)	0	5	2
Vomiting			
subjects affected / exposed	0 / 30 (0.00%)	2 / 32 (6.25%)	0 / 20 (0.00%)
occurrences (all)	0	2	0
Constipation			
subjects affected / exposed	1 / 30 (3.33%)	2 / 32 (6.25%)	2 / 20 (10.00%)
occurrences (all)	1	3	2
Abdominal pain upper			
subjects affected / exposed	0 / 30 (0.00%)	2 / 32 (6.25%)	1 / 20 (5.00%)
occurrences (all)	0	2	1
Skin and subcutaneous tissue disorders			
Rash			
subjects affected / exposed	2 / 30 (6.67%)	3 / 32 (9.38%)	1 / 20 (5.00%)
occurrences (all)	2	3	1
Eczema			
subjects affected / exposed	1 / 30 (3.33%)	1 / 32 (3.13%)	0 / 20 (0.00%)
occurrences (all)	1	1	0
Pruritus			
subjects affected / exposed	2 / 30 (6.67%)	7 / 32 (21.88%)	1 / 20 (5.00%)
occurrences (all)	2	7	1
Rash maculo-papular			
subjects affected / exposed	1 / 30 (3.33%)	1 / 32 (3.13%)	2 / 20 (10.00%)
occurrences (all)	1	1	2
Endocrine disorders			
Hypothyroidism			
subjects affected / exposed	1 / 30 (3.33%)	0 / 32 (0.00%)	0 / 20 (0.00%)
occurrences (all)	1	0	0
Musculoskeletal and connective tissue disorders			
Muscle spasms			

subjects affected / exposed	0 / 30 (0.00%)	0 / 32 (0.00%)	0 / 20 (0.00%)
occurrences (all)	0	0	0
Bone pain			
subjects affected / exposed	0 / 30 (0.00%)	1 / 32 (3.13%)	0 / 20 (0.00%)
occurrences (all)	0	1	0
Back pain			
subjects affected / exposed	1 / 30 (3.33%)	0 / 32 (0.00%)	2 / 20 (10.00%)
occurrences (all)	1	0	2
Arthralgia			
subjects affected / exposed	1 / 30 (3.33%)	1 / 32 (3.13%)	0 / 20 (0.00%)
occurrences (all)	1	1	0
Muscular weakness			
subjects affected / exposed	0 / 30 (0.00%)	0 / 32 (0.00%)	0 / 20 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
COVID-19			
subjects affected / exposed	1 / 30 (3.33%)	0 / 32 (0.00%)	2 / 20 (10.00%)
occurrences (all)	1	0	2
Pneumonia			
subjects affected / exposed	2 / 30 (6.67%)	1 / 32 (3.13%)	0 / 20 (0.00%)
occurrences (all)	2	1	0
Urinary tract infection			
subjects affected / exposed	1 / 30 (3.33%)	1 / 32 (3.13%)	0 / 20 (0.00%)
occurrences (all)	1	1	0
Upper respiratory tract infection			
subjects affected / exposed	0 / 30 (0.00%)	1 / 32 (3.13%)	0 / 20 (0.00%)
occurrences (all)	0	1	0
Metabolism and nutrition disorders			
Hypercalcaemia			
subjects affected / exposed	2 / 30 (6.67%)	0 / 32 (0.00%)	0 / 20 (0.00%)
occurrences (all)	3	0	0
Decreased appetite			
subjects affected / exposed	0 / 30 (0.00%)	1 / 32 (3.13%)	0 / 20 (0.00%)
occurrences (all)	0	1	0
Hyperglycaemia			

subjects affected / exposed	1 / 30 (3.33%)	3 / 32 (9.38%)	1 / 20 (5.00%)
occurrences (all)	1	3	1
Hypernatraemia			
subjects affected / exposed	0 / 30 (0.00%)	0 / 32 (0.00%)	0 / 20 (0.00%)
occurrences (all)	0	0	0
Hyperuricaemia			
subjects affected / exposed	0 / 30 (0.00%)	1 / 32 (3.13%)	0 / 20 (0.00%)
occurrences (all)	0	1	0
Hypokalaemia			
subjects affected / exposed	2 / 30 (6.67%)	1 / 32 (3.13%)	0 / 20 (0.00%)
occurrences (all)	2	1	0

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
13 October 2021	Amendment 2: To incorporate changes requested by various country Health Authorities (Germany, Spain, France, and Denmark)
04 March 2022	Amendment 3: Addition of an inclusion criterion pertaining to prior use of brentuximab vedotin in Cohort B participants with cHL in Germany-specific requirements per the Federal Institute for Drugs and Medical Devices (BfArM) request. In addition, added an exception for participants in Cohort E who are unable to receive all regionally approved therapies as part of their prior lines of treatment. Minor discrepancies were corrected for clarification.
29 August 2022	Amendment 4: Merck Sharp & Dohme Corp. underwent an entity name and address change to Merck Sharp & Dohme LLC, Rahway, NJ, USA. This conversion resulted only in an entity name change and update to the address.
16 February 2024	Amendment 5: To redefine the end of the study language, because the study primary objective has been met and additional data are not required.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported